Revolutionary ALS Treatment Passes Clinical Trial
Amyotrophic lateral sclerosis, or ALS, or Lou Gehrig’s disease, destroys nerves that control muscles. It currently has only one FDA approved medication for treatment, which reportedly has only a marginal effect.
Bioscience Technology reports, however, that an investigational new treatment for an inherited form of the disease has passed an early phase clinical trial. The treatment allows the mutated gene that causes ALS to be shut off and those that participated in the clinical trial reported no serious side effects.
This technique had never before been used in diseases where nerve damage occurs in the brain or spinal cord and researcher are optimistic that these results can help not only ALS patients, but the technique could also be used for other central nervous system disorders stemming from mutated genes, which include Huntington’s disease, Parkinson’s and Alzheimer’s.